




Gynaecology Expert Advisory Group:

Standards of Care for the Gynaecology Cancer Multidisciplinary Meeting (MDM) and Specialist Multidisciplinary Meeting (SMDM).

West Midlands Cancer Alliance

Coversheet for Cancer Alliance Expert Advisory Group Agreed Documentation

This sheet is to accompany all documentation agreed by the West Midlands Cancer Alliance Expert Advisory Groups. This will assist the Cancer Alliance to endorse the documentation and request implementation.

EAG Name	Gynaecology	
Document Title	<i>Standards of Care for the Gynaecology Cancer Multidisciplinary Meeting (MDM) and Specialist Multidisciplinary Meeting (SMDM).</i>	
Published Date	24 September 2021	
Document Purpose	This Standard of Care (SOC) document concerns details of how patients should be streamlined within the framework of gynaecology MDM/SMDMs for all trusts within the West Midlands Cancer Alliance.	
Authors	Janos Balega and all members of the Gynaecology EAG	
Review Date (must be within three years)	24 September 2024	
Approval Signatures:	EAG Chair  Janos Balega 24 September 2021	Cancer Alliance Clinical Director  Rob Gornall 24 September 2021



Standards of Care for the Gynaecology Cancer Multidisciplinary Meeting (MDM) and Specialist Multidisciplinary Meeting (SMDM)

Introduction:

This Standard of Care (SOC) document concerns details of how patients should be streamlined within the framework of gynaecology MDM/SMDMs for all trusts within the West Midlands Cancer Alliance.

It is envisioned that 'streamlining' will maximise MDM/SMDM management discussions for patients with complex gynaecology cancer disease that requires a full multidisciplinary approach, while protocolising the management of patients with less complex disease for which national guidelines (e.g. EAU, NICE & AUA) and West Midlands Cancer Alliance Gynaecology Expert Advisory Group are sufficient for decision-making.

Furthermore, the streamlining of MDMs/SMDMs is expected to encourage and foster a learning environment for all clinicians and students involved in the process.

Risk stratification of patients for MDM/SMDM discussion:

All new cancer patients must be listed for the MDM/SMDM.

All patients should be considered for clinical trials.

Criteria for discussion at MDM/SMDM are:

Predetermined Standards of Care – Gynaecology

Risk Group	Standard of Care Guidelines
Vulva	Preinvasive disease – not for discussion. If cancer diagnosed - discuss all new cases at diagnosis and after surgery in SMDM. Use BGCS Vulval Cancer guideline.
Cervix	Stage 1A1 and 1A2 – management done at unit level. All new cases to be discussed in the MDM at diagnosis and after surgery. Consider specialist pathology review of early stage cervical cancer cases. All other stages of cancer to be listed and discussed at SMDM at diagnosis with pathology and imaging review. Use BGCS Cervical Cancer Guideline



Adnexal mass – preoperatively	All cases to be listed and discussed at MDM with imaging review. Use RCOG Green-top Guideline No. 34. On the Management of Ovarian Cysts in Postmenopausal Women and No. 62. On the Management of Suspected Ovarian Masses in Premenopausal Women.
Adnexal mass – postoperatively	Pathology review: Benign cysts - no MDM listing required. Ovarian cancer – All cases to be listed for SMDM pathology discussion.
Endometrial cancer	All new cases to be listed and discussed at MDM at diagnosis for pathology and imaging review. Decisions to be protocolised as per local guidance. All high grade endometrial cancer discussed in SMDM. After surgery, all cases should have pathology review: Early stages (stage 1-2) should be protocolised. Use BGCS Endometrial Cancer Guideline
Suspected advanced ovarian cancer	Unit level MDT discussion at diagnosis. SMDM discussion of imaging at diagnosis, after NACT, and at first recurrence. Use BGCS Ovarian cancer guideline
Recurrences	All cancers with first recurrence should be listed and discussed at SMDM. All subsequent recurrences to be discussed at SMDM at clinicians' discretion

West Midlands Cancer Alliance, Gynaecology Expert Advisory Group, September 2021.

